Adverse reactions  Studies  Total patients, n  Patients with adverse reactions, n (%)  (%, min-max) †
Skin reactions
   Erythema ‡  [ 19, 32, 64, 66, 82, 95]  2352  201 (9)  (3–95) [ 95] - [ 82]
   Itching/Pruritus ‡  [ 6, 55, 57, 64, 66, 72, 82, 93]  3421  215 (6)  (0–70) [ 55] - [ 82]
   Urticaria ‡  [ 24, 31, 83]  58  9 (16)  (4–59) [ 24] - [ 83]
   Rash  [ 29, 30, 55, 57, 64, 93, 101, 111]  2682  121 (5)  (1–40) [ 30] - [ 93]
   Paresthesia/burning or  stinging sensation § ‡  [ 17, 21, 24, 28, 30, 44, 45, 55, 57, 67, 69, 79, 91, 93, 106]  2141  335 (16)  (0–100) [ 30] - [ 45]
   Scaling of skin/desquamation/  dry skin/local irritant ‡  [ 22, 29, 30, 37, 52, 55, 57, 64, 66, 69, 75, 82, 88, 89, 106]  4739  731 (15)  (1–96) [ 66] - [ 52]
   Blistering ‡  [ 31, 32, 66, 69, 93, 112]  2038  79 (4)  (3–20) [ 66] - [ 112]
   Roughness and/or thickening  of skin ‡  [ 66, 82, 93]  1986  191 (10)  (6–10) [ 93] - [ 82]
   Bullous dermatitis/dermatitis  with vesicles ‡  [ 20, 29, 64]  1116  79 (7)  (1–9) [ 64] - [ 29]
   Contact dermatitis ‡  [ 6, 20, 28– 30, 64, 111]  2587  161 (6)  (1–13) [ 28] - [ 29]
   Skin reaction, unspecified ‡  [ 2, 78, 96, 113]  457  159 (35)  (4–48) [ 96] - [ 113]
   Increase in skin pigmentation ‡  [ 6]  548  28 (5)
   Peripheral edema ‡  [ 45, 55, 66, 109]  2291  22 (0)  (1–14) [ 66] - [ 109]
Allergic reactions  [ 37, 44, 59, 86, 98, 110]  309  75 (24)  (3–55) [ 44, 110] - [ 86]
  Intravenous administration  [ 59, 86, 98, 110]  229  66 (29)  (2–55) [ 59] - [ 86]
  Transdermal application  [ 37, 44]  86  9 (10)  (3–19) [ 44] - [ 37]
  Flushing ¶  [ 41, 54, 73]  292  34 (12)  (2–9) [ 54] - [ 73]